Volume 7.14 | Apr 16

Cord Blood News 7.14 April 16, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
Assessment of Cell Viability, Early Apoptosis, and Hematopoietic Potential in Umbilical Cord Blood Units after Storage
Sixty cord blood (CB) units that had been cryopreserved for up to eight years in a single public CB bank were investigated. After the CB units were thawed, cell viability and early apoptosis of total nucleated cells, mononuclear cells, and CD34+ cells were determined using flow cytometric method based on 7-aminoactinomycin D and annexin V staining. [Transfusion] Abstract
Get More of the Cells You Need with StemSpan™ Erythroid Expansion Supplement and StemSpan™ SFEM
PUBLICATIONS (Ranked by impact factor of the journal)
Autologous Stem-Cell Transplantation without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses
Because of Jehovah’s Witnesses’ (JW) refusal of blood products, treatment challenges arise. This study represents 125 JWs with lymphoma, multiple myeloma, or amyloidosis, treated with high-dose chemotherapy and autologous stem-cell transplantation without transfusions [J Clin Oncol] Abstract

Donor CD4 T Cell Diversity Determines Virus Reactivation in Patients after HLA-Matched Allogeneic Stem Cell Transplantation
Scientists studied the T cell receptor beta gene rearrangements of flow cytometry-sorted CD4+ and CD8+ T cells from the peripheral blood of 23 allogeneic donors before granulocyte colony-stimulating factor administration and on the day of apheresis. [Am J Transplant] Full Article

Treatment of Collagen-Induced Arthritis Using Immune Modulatory Properties of Human Mesenchymal Stem Cells
Researchers investigated the potential therapeutic effects of human bone marrow-, adipose tissue-, and cord blood-derived mesenchymal stem cells (MSCs) in an experimental animal model of rheumatoid arthritis, and explored the mechanism underlying immune modulation by MSCs. [Cell Transplant] Full Article

Leukemia Cell Mobilization with G-CSF plus Plerixafor during Busulfan-Fludarabine Conditioning for Allogeneic Stem Cell Transplantation
Investigators compared the clinical effects and outcomes of AML/myelodysplastic syndrome study patients with 164 patients from a historical data set who received busulfan-fludarabine alone before allogeneic stem cell transplant by stratifying on cytogenetics and disease status to correct for bias. [Bone Marrow Transplant] Abstract

Autologous Stem Cell Transplantation versus Novel Drugs or Conventional Chemotherapy for Patients with Relapsed Multiple Myeloma after Previous ASCT
Researchers retrospectively studied the outcome of second-line treatment in multiple myeloma patients from the Nordic countries with relapse after first-line high-dose therapy and autologous stem cell transplantation (ASCT). [Bone Marrow Transplant] Abstract

Experience with Alemtuzumab Fludarabine, and Melphalan Reduced Intensity Conditioning Hematopoietic Cell Transplantation in over 200 Patients with Non-Malignant Diseases Reveals Good Outcomes and that Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen
Investigators conducted a retrospective study of 206 patients with metabolic diseases, non-Fanconi anemia marrow failure disorders, and primary immune deficiencies who underwent 210 consecutive RIC HCT procedures at Cincinnati Children’s Hospital. [Biol Blood Marrow Transplant] Abstract

Cell Type-Dependent Variation in Paracrine Potency Determines Therapeutic Efficacy against Neonatal Hyperoxic Lung Injury
Scientists determined the optimal cell type for transplantation to protect against neonatal hyperoxic lung injury. The in vitro and in vivo therapeutic efficacies and paracrine potencies of human umbilical cord blood-derived mesenchymal stromal cells, human adipose tissue-derived mesenchymal stromal cells and human umbilical cord blood mononuclear cells were compared. [Cytotherapy] Full Article

Outcomes of Mismatched and Unrelated Donor Hematopoietic Stem Cell Transplantation in Fanconi Anemia Conditioned with Chemotherapy Only
Investigators present their experience with 17 Fanconi anemia patients who completed mismatched related or unrelated donor hematopoietic stem cell transplantation using a non-radiation fludarabine-based preparative regimen. [Ann Hematol] Abstract

View Data: StemSpan™ SFEM II Serum-Free Medium
Prophylactic and Therapeutic Treatment of Graft-versus-Host Disease in Japan
Retrospective and non-randomized prospective studies suggest that cyclosporine A-based and tacrolimus-based graft-versus-host disease (GvHD) prophylaxis regimens are well researched and nearly optimized for Japanese patients, including infusion methods and target blood concentration. The author provides a baseline for starting prospective studies to create new evidence for GvHD treatment from Japan. [Int J Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Cord Blood Registry® Uses BioLife Solutions CryoStor® Clinical Grade Freeze Media in the Storage of Umbilical Cord Tissue Stem Cells
BioLife Solutions, Inc. announced that Cord Blood Registry uses BioLife’s CryoStor clinical grade cryopreservation freeze media in its process for cryogenic storage of umbilical cord tissue stem cells. [BioLife Solutions, Inc.] Press Release

Cardio3 BioSciences Enrolls First Patient in Phase I Trial for NKG2D CAR T-Cell
Cardio3 BioSciences announced the enrollment of the first patient in a Phase I clinical trial evaluating the Company’s lead CAR T-Cell therapy, NKG2D CAR T-Cell, in blood cancer patients with acute myeloid leukemia or multiple myeloma. [Cardio3 BioSciences S.A.] Press Release

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Therapy Bioprocessing & Commercialization
September 30-October 1, 2015
Alexandria, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Fellow – Stem Cell Trans Regulation (BloodCenter of Wisconsin)

NEW Postdoctoral Fellow – Hematopoietic Stem Cell Biology (University of Leuven)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Hematopoietic Stem Cell Research (Lund University)

Postdoctoral Research Fellow – Stem Cell/Hematopoiesis Research (BloodCenter of Wisconsin)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University School of Medicine)

Postdoctoral Fellows – Leukemia Research and Stem Cell Biology (Josep Carreras Leukemia Research Institute)

PhD Studentships – Expansion of Umbilical Cord Blood Stem Cells (University College London)

Cord Tissue Processing Technician (Cord Blood Registry)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us